Results 71 to 80 of about 2,435 (141)

Effect of elexacaftor-tezacaftor-ivacaftor therapy on systemic inflammation in people with cystic fibrosis. [PDF]

J Bras Pneumol
Meyer VMC, Aranha Netto N, Palmeira P, Athanazio RA, Silva-Filho LVRFD.   +4 more
europepmc   +1 more source

Clinical Outcomes in Concurrent Cohorts of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA)-Treated versus ELX/TEZ/IVA-Ineligible Individuals with Cystic Fibrosis in the US during COVID-19. [PDF]

Pulm Ther
Merlo CA, Romdhani H, DerSarkissian M, Muthukumar A, McGarry LJ, Lou Y, Van Brunt K.   +6 more
europepmc   +1 more source

Elexacaftor, Tezacaftor, and Ivacaftor

American Journal of Health-System Pharmacy, 2020
openaire   +1 more source

Altered functional interactions between CFTR disease mutants ΔF508 and G551D and the protein kinase A catalytic subunit. [PDF]

J Physiol
Závoti O, Simon MA, Csanády L.
europepmc   +1 more source

12-month outcomes of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in rare CFTR missense variant. [PDF]

Genet Med Open
Vekaria S, Al-Abbasi H, Mulrennan S.
europepmc   +1 more source

Management of Infants Exposed to Prenatal and Postnatal Elexacaftor/Tezacaftor/Ivacaftor: A Cross-Sectional Survey. [PDF]

Health Sci Rep
Haskett H, Ren CL.
europepmc   +1 more source

Off-label treatment with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: real-world evidence from the German CF Registry. [PDF]

ERJ Open Res
Stahl M, Gerts FS, Hafkemeyer S, Wosniok J, Naehrlich L, German CF Registry of the Mukoviszidose e.V. and participating sites.   +5 more
europepmc   +1 more source

Prenatal Elexacaftor/Tezacaftor/Ivacaftor for Fetal Meconium Ileus: First Italian Case and Narrative Overview of the Emerging Evidence. [PDF]

J Clin Med
Boni A, Vassallo C, Ciciriello F, Cristiani L, Mancini A, Zucaro L, Graziano S, Goffredo BM, Alghisi F, Raponi M, Fabietti I, On Behalf Of Opbg Cf Pregnancy And Fetal Therapy Multidisciplinary Group.   +11 more
europepmc   +1 more source

Long-Term Adherence to Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis. [PDF]

Pulm Ther
Hansen CME, Zendaky B, Zwitserloot AM, van den Bemt PMLA, van Boven JFM.   +4 more
europepmc   +1 more source

Correction to: Improved quality of life in cystic fibrosis patients observed up to 36 months after starting Elexacaftor/Tezacaftor/Ivacaftor treatment. [PDF]

J Patient Rep Outcomes
Buniotto F, Tridello G, De Scolari A, Meneghelli I, Pintani E, Perobelli S, Cipolli M.   +6 more
europepmc   +1 more source